Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15)

Yoshinobu Matsuda, Tatsuya Morita, Shunsuke Oyamada, Keisuke Ariyoshi, Takuhiro Yamaguchi, Satoru Iwase

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction Dyspnoea is common in patients with interstitial lung disease (ILD) and often refractory to conventional treatment. Little is known about the efficacy of systemic morphine for dyspnoea in patients with ILD. The aim of this study is to estimate the efficacy of a single subcutaneous morphine injection for dyspnoea in patients with ILD. Methods and analysis We will conduct a multicentre, prospective, randomised, placebo-controlled, single-blinded phase II study of a single subcutaneous morphine injection for dyspnoea in patients with ILD. In patients with ILD who have dyspnoea at rest refractory to conventional treatment will be eligible for participation in this study. The morphine dose will be 2 mg. The primary endpoint is changes in dyspnoea intensity from baseline to 60 min after treatment as measured using an 11-point Numerical Rating Scale and compared between the morphine and placebo groups. Ethics and dissemination Ethical approval has been obtained by the Osaka City University Certified Review Board. The results of this study will be submitted for publication in an international peer-reviewed journal and the findings will be presented at international scientific conferences. Trial registration number jRCTs051190030; pre-results.

Original languageEnglish
Article numbere043156
JournalBMJ open
Volume11
Issue number5
DOIs
Publication statusPublished - 2021 May 18
Externally publishedYes

Keywords

  • clinical trials
  • interstitial lung disease
  • palliative care

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15)'. Together they form a unique fingerprint.

Cite this